Disruptive Health Solutions Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 2.20 Cr
as on 19-12-2024
- Company Age 10 Year, 21 Days
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 9.50 Cr
as on 19-12-2024
- Revenue -45.23%
(FY 2021)
- Profit -37.99%
(FY 2021)
- Ebitda -11.55%
(FY 2021)
- Net Worth -276.77%
(FY 2021)
- Total Assets -1.87%
(FY 2021)
About Disruptive Health Solutions
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.20 Cr.
The company currently has active open charges totaling ₹9.50 Cr.
Akshay Navaladi and Ramesh Navaladi serve as directors at the Company.
- CIN/LLPIN
U85100DL2014PTC274801
- Company No.
274801
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2014
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Disruptive Health Solutions?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akshay Navaladi  | Director | 30-Dec-2014 | Current |
| Ramesh Navaladi | Director | 15-Jul-2019 | Current |
Financial Performance of Disruptive Health Solutions.
Disruptive Health Solutions Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 45.23% decrease. The company also saw a substantial fall in profitability, with a 37.99% decrease in profit. The company's net worth observed a substantial decline by a decrease of 276.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Disruptive Health Solutions?
In 2021, Disruptive Health Solutions had a promoter holding of 51.04% and a public holding of 48.96%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Fenway Pharmaceuticals Private LimitedActive 3 years 7 months
Akshay Navaladi and Ramesh Navaladi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Mar 2022 | ₹1.50 Cr | Open |
Others Creation Date: 18 Mar 2021 | ₹8.00 Cr | Open |
How Many Employees Work at Disruptive Health Solutions?
Disruptive Health Solutions has a workforce of 79 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Disruptive Health Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Disruptive Health Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
